Israel Englander Ocuphire Pharma, Inc. Transaction History

Millennium Management LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.89 - $3.27 $93,059 - $161,008	-49,238 Reduced 57.34%	36,628 $73,000
Q4 2023 Feb 14, 2024	BUY	$2.59 - $3.64 $222,392 - $312,552	85,866 New	85,866 $258,000
Q3 2022 Nov 14, 2022	SELL	$1.82 - $2.79 $20,236 - $31,022	-11,119 Reduced 31.25%	24,463 $49,000

2.55M

14.1K

800

Ticker OCUP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,579,800
Market Cap $21.8M
Description
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.